Calreticulin mutants as oncogenic rogue chaperones for TpoR and traffic-defective pathogenic TpoR mutants.

Calreticulin (CALR) +1 frameshift mutations in exon 9 are prevalent in myeloproliferative neoplasms. Mutant CALRs possess a new C-terminal sequence rich in positively charged amino acids, leading to activation of the thrombopoietin receptor (TpoR/MPL). We show that the new sequence endows the mutant CALR with rogue chaperone activity, stabilizing a dimeric state and transporting TpoR and mutants thereof to the cell surface in states that would not pass quality control; this function is absolutely required for oncogenic transformation. Mutant CALRs determine traffic via the secretory pathway of partially immature TpoR, as they protect N117-linked glycans from further processing in the Golgi apparatus. A number of engineered or disease-associated TpoRs such as TpoR/MPL R102P, which causes congenital thrombocytopenia, are rescued for traffic and function by mutant CALRs, which can also overcome endoplasmic reticulum retention signals on TpoR. In addition to requiring N-glycosylation of TpoR, mutant CALRs require a hydrophobic patch located in the extracellular domain of TpoR to induce TpoR thermal stability and initial intracellular activation, whereas full activation requires cell surface localization of TpoR. Thus, mutant CALRs are rogue chaperones for TpoR and traffic-defective TpoR mutants, a function required for the oncogenic effects.

[1]  N. Komatsu,et al.  Homomultimerization of mutant calreticulin is a prerequisite for MPL binding and activation , 2018, Leukemia.

[2]  P. Cresswell,et al.  Tumor-associated calreticulin variants functionally compromise the peptide loading complex and impair its recruitment of MHC-I , 2018, The Journal of Biological Chemistry.

[3]  E. Chen,et al.  Defining the requirements for the pathogenic interaction between mutant calreticulin and MPL in MPN. , 2018, Blood.

[4]  C. Pecquet,et al.  An incomplete trafficking defect to the cell-surface leads to paradoxical thrombocytosis for human and murine MPL P106L. , 2016, Blood.

[5]  C. Pecquet,et al.  Crispr/Cas9 Engineered 61bp Deletion in the Calr Gene of Mice Leads to Development of Thrombocytosis , 2016 .

[6]  T. Brümmendorf,et al.  Calreticulin-mutant proteins induce megakaryocytic signaling to transform hematopoietic cells and undergo accelerated degradation and Golgi-mediated secretion , 2016, Journal of Hematology & Oncology.

[7]  F. Al-Shahrour,et al.  Mutant Calreticulin Requires Both Its Mutant C-terminus and the Thrombopoietin Receptor for Oncogenic Transformation. , 2016, Cancer discovery.

[8]  C. Pecquet,et al.  Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants. , 2016, Blood.

[9]  N. Komatsu,et al.  Activation of the thrombopoietin receptor by mutant calreticulin in CALR-mutant myeloproliferative neoplasms. , 2016, Blood.

[10]  C. Pecquet,et al.  Calreticulin mutants in mice induce an MPL-dependent thrombocytosis with frequent progression to myelofibrosis. , 2016, Blood.

[11]  C. Pecquet,et al.  Pathologic activation of thrombopoietin receptor and JAK2-STAT5 pathway by frameshift mutants of mouse calreticulin , 2016, Leukemia.

[12]  Brock F. Binkowski,et al.  NanoLuc Complementation Reporter Optimized for Accurate Measurement of Protein Interactions in Cells. , 2016, ACS chemical biology.

[13]  C. Pecquet,et al.  Thrombopoietin receptor is required for the oncogenic function of CALR mutants , 2016, Leukemia.

[14]  B. Druker,et al.  Mutant calreticulin‐expressing cells induce monocyte hyperreactivity through a paracrine mechanism , 2016, American journal of hematology.

[15]  S. Constantinescu,et al.  His499 Regulates Dimerization and Prevents Oncogenic Activation by Asparagine Mutations of the Human Thrombopoietin Receptor* , 2015, The Journal of Biological Chemistry.

[16]  K. Wood,et al.  NanoBRET--A Novel BRET Platform for the Analysis of Protein-Protein Interactions. , 2015, ACS chemical biology.

[17]  P. Nordlund,et al.  The cellular thermal shift assay for evaluating drug target interactions in cells , 2014, Nature Protocols.

[18]  G. Superti-Furga,et al.  Somatic mutations of calreticulin in myeloproliferative neoplasms. , 2013, The New England journal of medicine.

[19]  J. D. Fitzpatrick,et al.  Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. , 2013, The New England journal of medicine.

[20]  C. Pecquet,et al.  Orientation‐specific signalling by thrombopoietin receptor dimers , 2011, The EMBO journal.

[21]  D. Engelman,et al.  Thrombopoietin receptor activation: transmembrane helix dimerization, rotation, and allosteric modulation , 2011, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[22]  G. Kozlov,et al.  Structural Basis of Carbohydrate Recognition by Calreticulin* , 2010, The Journal of Biological Chemistry.

[23]  N. Fox,et al.  Compound heterozygous c-Mpl mutations in a child with congenital amegakaryocytic thrombocytopenia: functional characterization and a review of the literature. , 2009, Experimental hematology.

[24]  Manfred Stuhrmann,et al.  Familial thrombocytosis caused by the novel germ‐line mutation p.Pro106Leu in the MPL gene , 2009, British journal of haematology.

[25]  D. Jarvis,et al.  Protein N-glycosylation in the baculovirus-insect cell system. , 2007, Current drug targets.

[26]  A. Surolia,et al.  Isothermal titration calorimetric study defines the substrate binding residues of calreticulin. , 2006, Biochemical and biophysical research communications.

[27]  Mamoru Ito,et al.  A novel nonpeptidyl human c-Mpl activator stimulates human megakaryopoiesis and thrombopoiesis. , 2006, Blood.

[28]  T. Kirchhausen,et al.  Dynasore, a cell-permeable inhibitor of dynamin. , 2006, Developmental cell.

[29]  M. Ballmaier,et al.  Congenital amegakaryocytic thrombocytopenia: a retrospective clinical analysis of 20 patients , 2005, British journal of haematology.

[30]  J. Spivak,et al.  Mpl Baltimore: a thrombopoietin receptor polymorphism associated with thrombocytosis. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[31]  A. Helenius,et al.  Mutational analysis provides molecular insight into the carbohydrate-binding region of calreticulin: pivotal roles of tyrosine-109 and aspartate-135 in carbohydrate recognition. , 2004, Biochemistry.

[32]  S. Constantinescu,et al.  Active and inactive orientations of the transmembrane and cytosolic domains of the erythropoietin receptor dimer. , 2003, Molecular cell.

[33]  V. Broudy,et al.  Internalization of the thrombopoietin receptor is regulated by 2 cytoplasmic motifs. , 2003, Blood.

[34]  M. R. Leach,et al.  Localization of the Lectin, ERp57 Binding, and Polypeptide Binding Sites of Calnexin and Calreticulin* , 2002, The Journal of Biological Chemistry.

[35]  D. Y. Thomas,et al.  The Structure of calnexin, an ER chaperone involved in quality control of protein folding. , 2001, Molecular cell.

[36]  A. Helenius,et al.  ER quality control: towards an understanding at the molecular level. , 2001, Current opinion in cell biology.

[37]  C J Thomas,et al.  Kinetics and the Mechanism of Interaction of the Endoplasmic Reticulum Chaperone, Calreticulin, with Monoglucosylated (Glc1Man9GlcNAc2) Substrate* , 2000, The Journal of Biological Chemistry.

[38]  Roland L. Dunbrack,et al.  Signals for retention of transmembrane proteins in the endoplasmic reticulum studied with CD4 truncation mutants. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[39]  J. Lippincott-Schwartz,et al.  Rapid redistribution of Golgi proteins into the ER in cells treated with brefeldin A: Evidence for membrane cycling from Golgi to ER , 1989, Cell.

[40]  Y. Misumi,et al.  Novel blockade by brefeldin A of intracellular transport of secretory proteins in cultured rat hepatocytes. , 1986, The Journal of biological chemistry.

[41]  A. Takatsuki,et al.  [Inhibitors affecting synthesis and intracellular translocation of glycoproteins as probes]. , 1985, Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme.

[42]  M. Ballmaier,et al.  c-mpl mutations are the cause of congenital amegakaryocytic thrombocytopenia. , 2001, Blood.